Individuals Discontinuing Weight-Loss Injections Regain Pounds Far More Rapidly Compared to People Using Diet and Exercise

A recent study reveals that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end conventional lifestyle regimens.

Findings released in a prominent medical journal points out that while obese people often shed a large proportion of their total mass while on the medication, the mass comes back at an estimated rate of nearly a kilo each month after stopping.

"People using such drugs should be cognizant of the potential of quick rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb.

This pace of regain implies a return to original mass in about a year and a half.

Analyzing Treatments

The study, which looked at dozens of trials involving over 9,000 of patients, contrasted the results of these new drugs with conventional dieting.

The team note that individuals who lose weight through diet and exercise usually experience a more gradual weight regain—perhaps 100 grams monthly—after stopping.

The Reason for the Quick Rebound

Experts propose the mechanism of the jabs accounts for the heightened rebound.

The injections imitate a body's own chemical called glucagon-like peptide-1, which controls hunger.

"Long-term administration of GLP-1 levels far above than normal may cause the system to produce less of its endogenous hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.

"Stopping of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating far more likely."

An Ongoing Condition?

Health authorities recommend the jabs for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.

Many experts say that, considering the likelihood of weight regain, the therapy is often long-term.

This opinion is reinforced by pharmaceutical companies, who say that the results "emphasize the persistent character of obesity," similar to managing conditions like high blood pressure.

Patient Experiences

People who have discontinued the medication report a sudden return of hunger.

"I experienced a trigger flipping and I was suddenly ravenous," described a patient.

This difficulty is exacerbated if users have not developed lasting dietary or behavioural modifications during therapy.

Significant Use

Survey data indicate that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.

• Adoption is higher among females than men.
• The middle-aged demographic shows the greatest usage rates.
• A large proportion access the medications through private prescriptions rather than the NHS.

Finally, researchers emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent fix and lasting health benefits relies on ongoing lifestyle changes.